SEARCH LISTED COMPANY

Any AUS or NZ company

BROWSE

Browse Australian delisted companies

0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Browse terminated Australian managed funds

0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
SEARCH PRIVATE COMPANY

SEARCH FUNDS

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:

PSIRON LIMITED (PSX)

Click here for free access to this company's:
ASX, Legal & CGT Status

SHARE PRICES

(updated at weekends)

Former (or subsequent) names

 FROMTO
VIRALYTICS LIMITED28/12/2006
PSIRON LIMITED17/08/200028/12/2006
MEDICAL INNOVATIONS LIMITED17/08/2000

Shareholder links

Our website ranking of PSX: rating 5
(5 out of 5)
COMPANY WEBSITE:

 

REGISTRY:
Link Market Services,Level 21, 10 Eagle Street Brisbane QLD 4000
Tel : +61 7 3320 2200 or 1300 554 474
Fax : +61 2 9287 0303
RegistryWebsite RegistryEmail

Company details

Address: Level 1 , 82 Waterloo Road , NORTH RYDE , NSW, AUSTRALIA, 2113
Tel:  (02) 9889 1200 Fax: (02) 9889 1288

Date first listed: 15/10/1986
Company Secretary: Mr Bryan Dulhunty
Sector: Pharmaceuticals & Biotechnology
Industry Group: XHJ
Activities: Biotechnology company with a focus on virotherapy treatment for a range of cancers, including melanoma, breast and prostate

name changed to Viralytics Limited

28/12/2006

shares reinstated to quotation

31/08/2006

CBio advises of the sale of its investment in BresaGen at a substantial profit and the placing of shares at $6 per share - Psiron owns 1.2 million shares in CBio Limited (cost price $1.00 per share) - this represents 4.7% of the share capital of the company

14/08/2006

company clarifiies the cash flow numbers set out in the June Quarter Appendix 4c: "Staff costs (item 1.2a) for the quarter are shown as $142,000. Payments to directors and director related entities (item 1.24) are also shown as $142,000. Both of these numbers are correct, however should not be interpreted as being one and the same. The fact that the two figures are identical is purely coincidental. Simply, the composition of each of the numbers is different."

09/08/2006

company releases a copy of a presentation and updates on studies and trials

22/06/2006

company provides a general update covering matters in the notes below and advising that it intends to apply for requotation of its shares upon completion of the public offer

09/06/2006

company announces the formal completion of its "first in man" Phase I trial in Malignant Melanoma

05/06/2006

issues a prospectus and applies for the quotation of an additional 44m ordinary shares - via the prospectus the company seeks to raise approximately $6.6m via a non-renounceable rights issue ("Issue") of approximately 44,069,335 New Shares at a price of $0.15 each on the basis of one New Share for every four ordinary Shares held

31/05/2006

Analytica Limited (ALT) has today announced the formation of a joint venture company in Hong Kong with Zhejiang Lingyang Medical Apparatus Company of Linhai China and J & J Stamina company of Taiwan - the joint venture company is expected shortly to sign a license agreement with Analytica Ltd to manufacture and distribute Analytica new constant flow auto burette and Analytica's retractable needle and syringe technologies - Psiron owns 26.7% of the share capital of Analytica Ltd

16/05/2006

CBio Limited announces the completion of the first Phase 2a trial in Rheumatoid Arthritis in 23 patients - CBio is also concluding studies in both Phase II clinical trials in multiple sclerosis and psoriasis (Psiron owns 1.2 million shares in CBio Limited, 5% of the share capital of the company)

09/05/2006

company advises it is working towards completing a private placement of up to 23.0 million new ordinary shares at 15 cents per share to raise up to $3.45 million - as of today's date, it has completed the placement of 12.0 million shares ($1.8 million) - based on commitments received, it is expected that additional shares will be placed shortly

04/05/2006

quarterly cash flow report to 31 March 2006 shows a deficit at operating level of $1619k

01/05/2006

company appoints AXIS Financial Group as financial advisers

19/04/2006

the company has today been advised by DFS Equities that its current funding proposal has lapsed - the company is currently reviewing alternative funding proposals and is confident that a long term funding option for the company will be announced in the near future

11/04/2006

shares suspended from quotation pending release of an announcement regarding the company's long term funding

10/04/2006

name changed from Medical Innovations Limited

17/08/2000

ASX Announcements (courtesy of ASX)

 

Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.

 

Company Updates

Post your comments here

Please read our Terms before posting comments.
OMISSIONS
    You can post a comment here about this company

    Please click in the "I'm not a robot" box. If an image appears, enter the word/figures you see in the image.

    loading Posting your comments. Please wait...

    Directors' on-market share transactions (last 5)

     

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    NAMETITLEDATE OF APPT
    Bryan DulhuntyExecutive Chairman, Finance Director10/04/2006
    Darren ShafrenDirector
    Dennis FeeneyDirector

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    NAMETITLEDATE OF APPOINTMENTDATE OF RESIGNATION

    Date of first appointment, title may have changed.